FMAU

N/A

Report date: 2022/08/23 20:00:44

Base Information

Drug NameFMAU
Drug Alias Name2'-fluoro-5-methylarabinosyluracilFM-ara-UNSC-67851618F-FMAU
ClassificationSmall molecules > Nucleosides and nucleotide derivtivesSmall molecules > Heterocyclic drugsRadiation-emitting products > Radioactive diagnostic agent
Mechanisms of ActionPositron-emission tomography enhancersDNA synthesis inhibitors
TargetsUpdating
Therapy Area/IndicationsSolid tumoursHerpes Simplex
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesMemorial Sloan Kettering Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBristol-Myers Squibb Company Bristol-Myers Squibb Holdings Pharma Ltd Liability CompanyMemorial Sloan Kettering Cancer Center
Active IndicationsN/A
Inactive IndicationsSolid tumoursHerpes Simplex

Other Information

ATC CodeN/A
Related LinksN/A